2021
Glucagon use by U.S. adults with type 1 and type 2 diabetes
Kahn PA, Liu S, McCoy R, Gabbay RA, Lipska K. Glucagon use by U.S. adults with type 1 and type 2 diabetes. Journal Of Diabetes And Its Complications 2021, 35: 107882. PMID: 33593689, PMCID: PMC8054027, DOI: 10.1016/j.jdiacomp.2021.107882.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1Emergency healthcare utilizationHigh-risk patientsAmerican Diabetes AssociationType 1 diabetesPrior hypoglycemiaPrescription patternsRisk patientsPrescription ratesHealthcare utilizationDiabetes AssociationDiabetes patientsAdministrative claimsPatientsGlucagon useDiabetesU.S. adultsGlucagonHypoglycemiaOptumLabs
2020
379-P: Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes
KAHN P, LIU S, MCCOY R, GABBAY R, LIPSKA K. 379-P: Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes. Diabetes 2020, 69 DOI: 10.2337/db20-379-p.Peer-Reviewed Original ResearchType 2 diabetesHigh-risk patientsType 1Diabetes patientsGlucagon useType 1 diabetes patientsAmerican Diabetes AssociationType 1 diabetesMedicare Advantage enrolleesPoor discriminative performanceGlucagon prescriptionsPrior hypoglycemiaRisk patientsDiabetes AssociationPrescribing practicesEndocrinology careMultivariable modelAdministrative claimsHigh riskPatientsType 2DiabetesModel AUCU.S. adultsGlucagon
2019
Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
McCoy R, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah N. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technology & Therapeutics 2019, 21: 702-712. PMID: 31418588, PMCID: PMC7207017, DOI: 10.1089/dia.2019.0213.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGlucose-lowering medicationsHeart failureKidney diseaseMyocardial infarctionHigh-quality diabetes careMedicare Advantage insurancePrevalent adverse effectsRenal protective benefitsTreatment-risk paradoxNationwide cohort studyCotransporter 2 inhibitorsGlucose-lowering therapyPrior myocardial infarctionGlucose lowering medicationsChronic diabetes complicationsMultivariable logistic regressionNon-black patientsType 2 diabetesDiabetes type 1Insurance-related factorsCommercial health insuranceAppropriateness of usePrior hypoglycemiaSGLT2i initiation
2018
Hospitalization and Emergency Department Visits for Severe Hypoglycemia among U.S. Adults with Diabetes and Serious Comorbid Conditions
MCCOY R, VAN HOUTEN H, LIPSKA K, SHAH N. Hospitalization and Emergency Department Visits for Severe Hypoglycemia among U.S. Adults with Diabetes and Serious Comorbid Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-381-p.Peer-Reviewed Original ResearchEnd-stage renal diseaseChronic kidney diseaseSevere hypoglycemiaChronic conditionsChronic obstructive pulmonary diseaseRate of hospitalSerious comorbid conditionsGlucose-lowering therapyNumber of comorbiditiesEmergency department visitsObstructive pulmonary diseaseStage renal diseaseEmergency department careRisk of hypoglycemiaLimited life expectancyOptumLabs Data WarehouseSpecific chronic conditionsHigh clinical complexityPrior hypoglycemiaDiabetes medicationsMultiple comorbiditiesGlycemic targetsHypoglycemia ratesUrinary incontinenceDepartment visits
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply